IP Library Granted Patent US 12,599,321
Granted Patent B2
US 12,599,321 · App. 17/864,907 · Granted Apr 14, 2026

Devices and methods for assessing pulmonary status using optical oxygenation sensing

Inventors: Jeffrey E. Stahmann (Ramsey, MN); Keith R. Maile (New Brighton, MN)
Assignee: Cardiac Pacemakers, Inc.
A61B5/1459A61B5/0205A61B5/14551A61B5/4842A61B5/6867A61B5/024A61B5/0816A61B5/091
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,321
App. No.
17/864,907
Granted
Apr 14, 2026
Kind
B2
Abstract

Embodiments herein relate to devices and methods for assessing pulmonary status using optical oxygenation sensing. In an embodiment, an oxygenation monitoring device can be included having a first optical emitter, wherein the first optical emitter can be configured to emit light at a first wavelength from 100 nanometers (nm) to 2000 nm. The oxygenation monitoring device and further include a first optical detector, wherein the first optical detector can be configured to detect incident light. The device can be configured so that emitted light from the first optical emitter propagates through a lung tissue and detected incident light can be used to determine an oxygenation status of the lung tissue. Other embodiments are also included herein.

Claims (44)

1 . An oxygenation monitoring device comprising:

an implantable housing defining an interior volume, the implantable housing comprising:

control circuitry disposed within the interior volume;

a first optical emitter coupled to the implantable housing and in electrical communication with the control circuitry, wherein the first optical emitter is configured to emit light at a first wavelength from 100 nanometers (nm) to 2000 nm;

a second optical emitter coupled to the implantable housing and in electrical communication with the control circuitry, wherein the second optical emitter is configured to emit light at a second wavelength that is different from the first wavelength; and

a first optical detector coupled to the implantable housing and in electrical communication with the control circuitry, wherein the first optical detector is configured to detect incident light;

wherein the first optical emitter is spaced a first distance away from the first optical detector along a planar surface of the device;

wherein the second optical emitter is spaced a second distance away from the first optical detector along the planar surface of the device, wherein the first distance is greater than the second distance;

wherein the emitted light from the first optical emitter propagates through the lung tissue simultaneously with the emitted light from the second optical emitter;

wherein emitted light from the first optical emitter propagates through a lung tissue to a first depth; and

wherein emitted light from the second optical emitter propagates through the lung tissue to a second depth, wherein the first depth is greater than the second depth;

wherein the control circuitry determines an oxygenation status of the lung tissue using a ratio of a first molar extinction coefficient at the first wavelength to a second molar extinction coefficient at the second wavelength; and

wherein the device is implantable in a subcutaneous tissue of a patient.

2 . The device of claim 1 , wherein the device is configured so that emitted light from the first optical emitter propagates through tissue at a depth of at least 1 cm as measured from a surface of the device and back to the first optical detector.

3 . The device of claim 1 , wherein the first wavelength is from 550 nm to 1000 nm.

4 . The device of claim 1 , wherein the first optical emitter and the first optical detector are spaced along a length of the oxygenation monitoring device at from 1 cm to 10 cm apart.

5 . The device of claim 1 , wherein the first wavelength is from 600 nm to 800 nm.

6 . The device of claim 1 , wherein the second wavelength is from 800 nm to 2000 nm.

7 . The device of claim 1 , wherein emitted light from the first optical emitter is propagated to a different depth than emitted light from the second optical emitter.

8 . The device of claim 1 , wherein the device is further configured to determine one of a heart rate, a respiratory rate, a tidal volume, or an extravascular lung water concentration using a secondary sensor.

9 . The device of claim 1 , further comprising:

a flexible member, wherein the flexible member is connected to the housing and extends in a direction away from the implantable housing.

10 . The device of claim 9 , wherein at least one of the first optical emitter and the optical detector are disposed along a length of the flexible member.

11 . The device of claim 1 , wherein the first optical emitter and the optical detector are spaced along the planar surface of the device from 1 cm to 10 cm apart.

12 . The device of claim 1 , wherein propagation of the emitted light through a lung tissue comprises propagation of the emitted light from 1 cm to 5 cm in depth as measured from a surface of the oxygenation monitoring device.

13 . The device of claim 1 , wherein the first optical emitter is disposed at least 6 cm away from the first optical detector.

14 . The device of claim 1 , wherein the emitted light from the first optical emitter propagates through the lung tissue at a depth of at least 3 cm as measured from a surface of the device and back to the first optical detector.

15 . A method for measuring an oxygenation status in a patient comprising:

bringing an oxygenation monitoring device into contact with a tissue of the patient, the oxygenation monitoring device comprising an optical sensor comprising:

an implantable housing defining an interior volume, the implantable housing comprising:

control circuitry disposed within the interior volume a first optical emitter coupled to the implantable housing and in electrical communication with the control circuitry, wherein the first optical emitter is configured to emit light at a first wavelength from 100 nanometers (nm) to 2000 nm;

a second optical emitter coupled to the implantable housing and in electrical communication with the control circuitry, wherein the second optical emitter is configured to emit light at a second wavelength that is different from the first wavelength; and

a first optical detector coupled to the implantable housing and in electrical communication with the control circuitry, wherein the first optical detector is configured to detect incident light;

wherein the first optical emitter is spaced a first distance away from the first optical detector along a planar surface of the device;

wherein the second optical emitter is spaced a second distance away from the first optical detector along the planar surface of the device, wherein the first distance is greater than the second distance;

implanting the oxygenation monitoring device subcutaneously at or near a site of a lung tissue so that the first light emitter and the first light detector are directed toward an interior of the patient toward a surface of the lung tissue;

propagating a first emitted light from the first optical emitter at the first wavelength to a region of the lung tissue at a first depth;

propagating a second emitted light from the second optical emitter at the second wavelength to a second region of the lung tissue at a second depth, wherein the first depth is greater than the second depth;

wherein the emitted light from the first optical emitter propagates through the lung tissue simultaneously with the emitted light from the second optical emitter;

detecting an incident light with the optical detector;

determining an oxygenation status of the lung tissue based on the detected incident light;

wherein determining the oxygenation status comprises performing a ratiometric calculation using a ratio of a first molar extinction coefficient at the first wavelength to a second molar extinction coefficient at the second wavelength.

16 . The method of claim 15 , wherein the first emitted light is propagated at a depth of from 1 cm to 5 cm into the lung tissue.

17 . The method of claim 15 , further comprising monitoring a progression or regression of one or more conditions comprising chronic obstructive pulmonary disease (COPD), pulmonary edema, asthma, pneumonia, airway obstruction, heart failure, acute respiratory distress syndrome (ARDS), septic shock, or pulmonary embolism.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: STAHMANN, JEFFREY E.; MAILE, KEITH R.
To: CARDIAC PACEMAKERS, INC.
Reel/Frame 061640/0015 →
Continuity (2)
Provisional Application 63223201 · Jul 19, 2021
Related Publication 20230017684A1 · Jan 19, 2023
References Cited (77)
US 6739335B1 · Rapport et al. · 2004 [cited by applicant]
US 7809441B2 · Kane et al. · 2010 [cited by applicant]
US 7813778B2 · Benaron et al. · 2010 [cited by applicant]
US 7865223B1 · Bernreuter · 2011 [cited by applicant]
US 8126554B2 · Kane et al. · 2012 [cited by applicant]
US 8320981B1 · Mayer · 2012 [cited by examiner]
US 8426819B2 · Herrmann · 2013 [cited by applicant]
US 8794236B2 · Phuah et al. · 2014 [cited by applicant]
US 9649070B2 · Seppä et al. · 2017 [cited by applicant]
US 10398863B2 · Phuah et al. · 2019 [cited by applicant]
US 10932674B2 · Luxon et al. · 2021 [cited by applicant]
US 11154249B2 · Kuhn · 2021 [cited by examiner]
US 12446782B2 · Stahmann et al. · 2025 [cited by applicant]
US 20020123674A1 · Plicchi et al. · 2002 [cited by applicant]
US 20040116789A1 · Boas et al. · 2004 [cited by applicant]
US 20060253016A1 · Baker et al. · 2006 [cited by applicant]
US 20090163819A1 · De Kok et al. · 2009 [cited by applicant]
US 20100022856A1 · Cinbis et al. · 2010 [cited by applicant]
US 20100043557A1 · Savery et al. · 2010 [cited by applicant]
US 20100106210A1 · Hedberg et al. · 2010 [cited by applicant]
US 20120190989A1 · Kaiser et al. · 2012 [cited by applicant]
US 20130310669A1 · Nitzan · 2013 [cited by applicant]
US 20140149065A1 · Pompei et al. · 2014 [cited by applicant]
US 20170135633A1 · Connor · 2017 [cited by examiner]
US 20170303815A1 · De Limon et al. · 2017 [cited by applicant]
US 20180073928A1 · Nakaya et al. · 2018 [cited by applicant]
US 20180344252A1 · An et al. · 2018 [cited by applicant]
US 20190320985A1 · LeBoeuf · 2019 [cited by examiner]
US 20190336077A1 · Kuhn · 2019 [cited by examiner]
US 20200000345A1 · Connor · 2020 [cited by applicant]
US 20200029827A1 · Tang et al. · 2020 [cited by applicant]
US 20200043591A1 · Kahlert et al. · 2020 [cited by applicant]
US 20200268536A1 · Dilorenzo · 2020 [cited by applicant]
US 20210045671A1 · Wiese · 2021 [cited by examiner]
US 20210161444A1 · Shao et al. · 2021 [cited by applicant]
US 20210361238A1 · Bak-Boychuk et al. · 2021 [cited by applicant]
US 20220095937A1 · Faircloth · 2022 [cited by applicant]
US 20220192600A1 · Bang et al. · 2022 [cited by applicant]
US 20220248993A1 · Dixon · 2022 [cited by applicant]
US 20220370010A1 · Zilkie et al. · 2022 [cited by applicant]
US 20230014499A1 · Stahmann et al. · 2023 [cited by applicant]
US 20230024917A1 · Stahmann et al. · 2023 [cited by applicant]
US 20230025497A1 · Stahmann et al. · 2023 [cited by applicant]
US 20230081138A1 · Stahmann et al. · 2023 [cited by applicant]
Beek, J.F., et al. “The optical properties of lung as a function of respiration,” Phys. Med. Biol. 42 (1997) 2263-2272 (10 pages). [cited by applicant]
Inaba, Kenti, et al. “Radiologic Evaluation of Alternative Sites for Needle Decompression of Tension Pneumothorax,” Arch Surg. 2012:147(9):813-818 (6 pages). [cited by applicant]
Lichtwarck-Aschoff, Michael, et al. “Decreasing size of cardiogenic oscillations reflects decreasing compliance of the respiratory system during long-term ventilation,” J. Appl. Physiol. 96; 879-884 (6 pages). [cited by applicant]
Martinsen, Paul, et al. “Temperature dependence of near-infrared spectra of whole blood,” Journal of Biomedical Optics 13(3), 034016 (May/Jun. 2008) (7 pages). [cited by applicant]
Schumann, S., et al. “Cardiogenic oscillations in spontaneous breathing airway signal reflect respiratory system mechanics,” Acta Anaesthesiol Scand 2011; 55: 980-986 (7 pages). [cited by applicant]
Suarez-Sipmann, Fernando, et al. “Pulmonary artery pulsatility is the main cause of cardiogenic oscillations,” J Clin Monit Comput (2013) 27:47-53 (7 pages). [cited by applicant]
Tusman, Gerardo, et al. “Pulmonary blood flow generates cardiogenic oscillations,” Respiratory Physiology & Neurobiology (2009) (8 pages). [cited by applicant]
Hwang, Chan-Sol, et al.“Angle-selective optical filter for highly sensitive reflection photoplethysmogram,” Biomedical Optics Express 4361, vol. 8, No. 10, 2017 (8 pages). [cited by applicant]
Johnston, Hamish “New material offers angular control over light,” Physics World, Mar. 27, 2014 (3 pages). [cited by applicant]
Qian, Qinyu, et al.“All-dielectric polarization-independent optical angular filter,” Scientific Reports, Nov. 29, 2017, 7: 16574 (7 pages). [cited by applicant]
Zakirullin, Rustam “Creating optical filters with angular-selective light transmission,” Applied Optics, 2015, vol. 54, No. 25 (5 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 17/866,023 mailed Jul. 8, 2024 (41 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 17/866,030 mailed May 8, 2024 (25 pages). [cited by applicant]
“Response to Non-Final Rejection,” mailed on May 8, 2024, for U.S. Appl. No. 17/866,030, submitted via EFS-Web on Aug. 8, 2024, 9 pages. [cited by applicant]
Meinhardt, Merve, et al. “Wavelength-dependent penetration depths of ultraviolet radiation in human skin,” Journal of Biomedical Optics 2008, 13(4), 044030-1 to 5. (Year: 2008). [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 17/866,023 mailed Nov. 25, 2024 (29 pages). [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 17/866,030 mailed Nov. 6, 2024 (25 pages). [cited by applicant]
“Response to Non-Final Rejection,” mailed on Jul. 8, 2024, for U.S. Appl. No. 17/866,023, submitted via EFS-Web on Oct. 8, 2024, 14 pages. [cited by applicant]
“Non-Final Office Action,” U.S. Appl. No. 17/864,899 mailed Jun. 16, 2025 (38 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 17/944,582 mailed Jul. 24, 2025, (30 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 17/866,023 mailed Mar. 27, 2025 (36 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 17/866,030 mailed May 8, 2025 (33 pages). [cited by applicant]
“Notice of Allowance,” for U.S. Appl. No. 17/866,023 mailed Jul. 21, 2025 (11 pages). [cited by applicant]
“Response to Final Rejection,” mailed on Nov. 6, 2024, for U.S. Appl. No. 17/866,030, submitted via Patent Center on Feb. 6, 2025, 13 pages. [cited by applicant]
“Response to Non-Final Rejection,” mailed on Mar. 27, 2025, for U.S. Appl. No. 17/866,023, submitted via Patent Center on Jun. 27, 2025, 12 pages. [cited by applicant]
“Response to Non-Final Rejection,” mailed on May 8, 2025, for U.S. Appl. No. 17/866,030, submitted via Patent Center on Aug. 6, 2025, 14 pages. [cited by applicant]
Ashley, Welch “The thermal response of laser irradiated tissue,” IEEE Journal of Quantum Electronics, vol. 20, No. 12, pp. 1471-1481, Dec. 1984, doi: 10.1109/JQE.1984.1072339. (11 pages). [cited by applicant]
Cotler, Howard B., et al.“The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain,” MOJ Orthop Rheumatol. 2015;2(5):00068. doi: 10.15406/mojor.2015.02.00068. Epub Jun. 9, 2015. PMID: 26858986; PMCID: PMC47436… [cited by applicant]
Henderson, Theodore A, et al.“Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain,” Neuropsychiatr Dis Treat. Aug. 21, 2015 ;11:2191-208. doi: 10.2147/NDT.S78182. PM ID… [cited by applicant]
“Response to Non-Final Rejection,” mailed on Jul. 24, 2025, for U.S. Appl. No. 17/944,582, submitted via Patent Center on Oct. 22, 2025, 11 pages. [cited by applicant]
“Response to Non-Final Rejection,” mailed on Jun. 16, 2025, for U.S. Appl. No. 17/864,899, submitted via Patent Center on Sep. 16, 2025, 12 pages. [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 17/866,030 mailed Nov. 24, 2025 (36 pages). [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 17/944,582 mailed Nov. 20, 2025 (16 pages). [cited by applicant]